Scotland Leads the UK in Newborn Screening for Spinal Muscular Atrophy
Scotland has become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA), a rare genetic condition that causes progressive muscle weakness. The move follows advocacy from campaigners and increased awareness, notably from singer Jesy Nelson, whose twin daughters were diagnosed with SMA in 2025.
Understanding Spinal Muscular Atrophy
Spinal Muscular Atrophy is a genetic disease affecting motor neurons, nerve cells in the spinal cord responsible for controlling muscle movement. Without treatment, SMA can severely limit life expectancy, sometimes to as little as two years . The condition impacts movement, breathing, and swallowing, and its severity varies depending on the type.
Types of SMA
SMA is classified into different types based on the age of onset and severity of symptoms. SMA type 1 is the most severe, typically appearing in infancy. SMA type 2 is less severe, and diagnosis may occur later in childhood.
The Importance of Early Detection
Early detection of SMA is critical due to the fact that treatment options are most effective when initiated before significant nerve cell damage occurs. Babies identified with SMA through a heel prick test can start treatment promptly, potentially prolonging their lives and improving their quality of life.
Jesy Nelson’s Advocacy
Former Little Mix singer Jesy Nelson publicly shared that her twin daughters, Ocean Jade and Story Monroe Nelson, were diagnosed with SMA in January 2025. She has since become a vocal advocate for universal newborn screening, highlighting the potential benefits of early intervention. Nelson launched a petition calling for SMA screening to be added to the newborn blood spot test, which garnered over 100,000 signatures and will be debated in the House of Commons.
Scotland’s New Screening Program
As part of a two-year pilot program, all babies born in Scotland will now be screened for SMA using the heel prick test, typically conducted around four days after birth. This initiative aims to identify affected infants early, allowing for timely access to treatment.
Treatment Options
Treatment for SMA has advanced significantly in recent years. One treatment involves a gene therapy infusion that delivers a functional copy of the missing gene to the body. While this therapy can halt the progression of muscle loss, it cannot restore muscle function that has already been lost.
Looking Ahead
The implementation of newborn screening for SMA in Scotland is a significant step forward in the fight against this devastating disease. Campaigners hope this pilot program will pave the way for nationwide screening across the UK, ensuring that all infants have the opportunity to benefit from early diagnosis and treatment.